Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 1:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 89 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Radical Cystectomy Clear all
Completed Not applicable Interventional

The Impact of Early Feeding After Radical Cystectomy for Bladder Cancer

NCT01489800
View directory record Official record
Conditions
Bladder Cancer, Complications
Interventions
Clear liquid diet
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 17, 2021 · Synced Oct 25, 2026, 1:48 PM EDT
Active, not recruiting Early Phase 1 Interventional

(CLONEVO): Cell cycLe inhbitiON to Target the EVolution of UrOthelial Cancer

NCT03837821
View directory record Official record
Conditions
Bladder Cancer
Interventions
Abemaciclib
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
2
States / cities
New York, New York • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 18, 2025 · Synced Oct 25, 2026, 1:48 PM EDT
Active, not recruiting Phase 3 Interventional

A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder

NCT04658862
View directory record Official record
Conditions
Urinary Bladder Neoplasms
Interventions
Cetrelimab, TAR-200, Cisplatin, Gemcitabine, Conventional radiation therapy, Hypo-fractioned radiation therapy
Biological · Drug · Radiation
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
518 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
28
States / cities
Loma Linda, California • Los Angeles, California • Santa Monica, California + 25 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 25, 2026, 1:48 PM EDT
Recruiting Not applicable Interventional

Clinical Trial to Evaluate Post-Operative Outcomes of Ureteral Stent vs Ureteral Stent Free Radical Cystectomy

NCT07234968
View directory record Official record
Conditions
Bladder Cancer, Muscle-Invasive Bladder Carcinoma, Urothelial Carcinoma, Pelvic Malignancy, Bladder Transitional Cell Carcinoma, Bladder Neoplasm
Interventions
Ureteral Stent Placement, No Ureteral Stent, Indocyanine Green with Fluorescence Imaging
Procedure · Diagnostic Test
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 85 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Oct 25, 2026, 1:48 PM EDT
Not listed Not applicable Interventional

Use of Pedometer Following Radical Cystectomy

NCT04305730
View directory record Official record
Conditions
Bladder Cancer, Ileus, Narcotic Use
Interventions
Use of a pedometer following surgery, Standard of care
Behavioral
Lead sponsor
Benaroya Research Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 16, 2021 · Synced Oct 25, 2026, 1:48 PM EDT
Withdrawn Phase 3 Interventional

Continuous Infusion of Ropivacaine Hydrochloride in Reducing Pain After Surgery in Patients With Bladder Cancer

NCT02438852
View directory record Official record
Conditions
Bladder Carcinoma, Post-operative Pain
Interventions
Placebo, Questionnaire Administration, Ropivacaine Hydrochloride
Other · Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 16, 2019 · Synced Oct 25, 2026, 1:48 PM EDT
Completed Not applicable Interventional Results available

Steps to Eliminate Postoperative Problems

NCT02880176
View directory record Official record
Conditions
Bladder Cancer
Interventions
Financial Incentive to Increase Ambulation
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
21 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 9, 2021 · Synced Oct 25, 2026, 1:48 PM EDT
Recruiting Phase 2 Interventional

Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC

NCT07322263
View directory record Official record
Conditions
Bladder Cancer, Non-Muscle Invasive Bladder Cancer (NMIBC), Urothelial Carcinoma, Carcinoma in Situ (CIS), High-Grade Papillary Bladder Tumors, BCG-Unresponsive Bladder Cancer, Ta Stage Bladder Cancer, T1 Stage Bladder Cancer, BCG-Refractory Bladder Cancer, High-Risk NMIBC, Micropapillary Variant Urothelial Carcinoma (Favorable Subtype)
Interventions
Intravesical Gemcitabine and Docetaxel
Drug
Lead sponsor
Michael A. O'Donnell
Other
Eligibility
18 Years to 99 Years
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Oct 25, 2026, 1:48 PM EDT
Recruiting Early Phase 1 Interventional

Prophylactic Antibiotics in Cystectomy With Diversion

NCT06190197
View directory record Official record
Conditions
Muscle-Invasive Bladder Carcinoma, Radical Cystectomy, Ileal Conduit, Neobladder Diversion
Interventions
Prophylactic antibiotics postoperatively.
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 17, 2025 · Synced Oct 25, 2026, 1:48 PM EDT
Completed Phase 2 Interventional Results available

Erlotinib Before and After Surgery in Treating Patients With Muscle-Invasive Bladder Cancer

NCT00380029
View directory record Official record
Conditions
Bladder Cancer
Interventions
Erlotinib, Radical Cystectomy
Drug · Procedure
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 19, 2017 · Synced Oct 25, 2026, 1:48 PM EDT
Terminated Phase 2 Interventional Results available

An Umbrella Study to Determine the Safety and Efficacy of Various Monotherapy or Combination Therapies in Neoadjuvant Urothelial Carcinoma

NCT04586244
View directory record Official record
Conditions
Urothelial Carcinoma
Interventions
retifanlimab, epacadostat, INCAGN02385, INCAGN02390
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
4
States / cities
Iowa City, Iowa • Cincinnati, Ohio • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2025 · Synced Oct 25, 2026, 1:48 PM EDT
Active, not recruiting Not applicable Interventional

Cystoscopic Evaluation Predicting pT0 Urothelial Carcinoma of the Bladder

NCT02968732
View directory record Official record
Conditions
Urothelial Carcinoma
Interventions
Radical Cystectomy
Procedure
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 25, 2026, 1:48 PM EDT
Completed Phase 1Phase 2 Interventional

Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage II or Stage III Bladder Cancer

NCT00003930
View directory record Official record
Conditions
Bladder Cancer
Interventions
cisplatin, gemcitabine hydrochloride, paclitaxel, conventional surgery, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2013
U.S. locations
210
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 166 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2020 · Synced Oct 25, 2026, 1:48 PM EDT
Completed Phase 2 Interventional Results available

BLASST-1 (Bladder Cancer Signal Seeking Trial): Nivolumab, Gemcitabine, and Cisplatin in Treatment of Muscle Invasive Bladder Cancer (MIBC) Undergoing Cystectomy

NCT03294304
View directory record Official record
Conditions
Muscle Invasive Bladder Cancer
Interventions
Nivolumab, Cisplatin, Gemcitabine
Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
3
States / cities
Boston, Massachusetts • Minneapolis, Minnesota • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 16, 2021 · Synced Oct 25, 2026, 1:48 PM EDT
Completed Phase 1 Interventional

Trial of Intravesical Measles Virotherapy in Patients With Bladder Cancer Who Are Undergoing Radical Cystectomy

NCT03171493
View directory record Official record
Conditions
Urothelial Carcinoma
Interventions
MV-NIS
Biological
Lead sponsor
Vyriad, Inc.
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
3
States / cities
Miami, Florida • New Orleans, Louisiana • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 27, 2023 · Synced Oct 25, 2026, 1:48 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Gabapentin in Reducing the Need for Pain Medication in Patients With Bladder Cancer Undergoing Radical Cystectomy

NCT02355886
View directory record Official record
Conditions
Bladder Carcinoma
Interventions
Gabapentin, Placebo, Questionnaire Administration
Drug · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 75 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 4, 2019 · Synced Oct 25, 2026, 1:48 PM EDT
Completed No phase listed Observational Results available

Perioperative Hypogonadism in Men Undergoing Radical Cystoprostatectomy for Bladder Cancer

NCT03063125
View directory record Official record
Conditions
Bladder Cancer, Low Testosterone Levels
Interventions
Not listed
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older · Male only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 3, 2021 · Synced Oct 25, 2026, 1:48 PM EDT
Completed Phase 2 Interventional Results available

Phase 2 Study of Pembrolizumab in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy

NCT02690558
View directory record Official record
Conditions
Bladder Cancer
Interventions
pembrolizumab, gemcitabine and cisplatin
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 20, 2026 · Synced Oct 25, 2026, 1:48 PM EDT
Recruiting Phase 2 Interventional

Assessment of Decision Tool to Select Women for Gynecologic Sparing Radical Cystectomy

NCT06184516
View directory record Official record
Conditions
Urothelial Carcinoma Bladder
Interventions
Reproductive organ sparing radical cystectomy, Radical cystectomy
Procedure
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 99 Years · Female only
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 25, 2026, 1:48 PM EDT
Completed Not applicable Interventional Results available

FITBIT Study on Mobility and Readmissions After Radical Cystectomy

NCT04314778
View directory record Official record
Conditions
Bladder Cancer
Interventions
social incentive-based gamification
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 24, 2024 · Synced Oct 25, 2026, 1:48 PM EDT
Recruiting Not applicable Interventional

Pre-Habilitation with Mindfulness and Exercise for Patients Undergoing Radical Cystectomy (PRIMER Trial)

NCT05790850
View directory record Official record
Conditions
Bladder Cancer, Non-muscle-invasive Bladder Cancer, Muscle-Invasive Bladder Carcinoma
Interventions
Pre-operative physical exercise, Pre-operative mindfulness meditation practice
Behavioral
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 90 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 16, 2024 · Synced Oct 25, 2026, 1:48 PM EDT
Completed Not applicable Interventional

CLEAR Care Companion Application

NCT05578898
View directory record Official record
Conditions
Bladder Cancer, Radical Cystectomy
Interventions
CLEAR Care Companion (CC) application
Behavioral
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 8, 2025 · Synced Oct 25, 2026, 1:48 PM EDT
Terminated Phase 2 Interventional Results available

Study of Gemcitabine, Carboplatin, and Panitumumab (GCaP) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer

NCT01916109
View directory record Official record
Conditions
Bladder Cancer
Interventions
Gemcitabine, Carboplatin, Panitumumab, radical cystectomy
Drug · Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
5
States / cities
Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2016 · Synced Oct 25, 2026, 1:48 PM EDT
Completed No phase listed Observational

Prediction of Impaired Survival in Elderly Bladder Cancer Patients Opting for Radical Cystectomy

NCT02039310
View directory record Official record
Conditions
Bladder Cancer
Interventions
Not listed
Lead sponsor
University of Michigan
Other
Eligibility
65 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 27, 2017 · Synced Oct 25, 2026, 1:48 PM EDT